SEK 101.1
(2.17%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 181.2 Million SEK | 26.86% |
2022 | 142.83 Million SEK | 39.03% |
2021 | 102.73 Million SEK | 42.14% |
2020 | 72.27 Million SEK | 5.6% |
2019 | 68.44 Million SEK | 54.81% |
2018 | 44.21 Million SEK | 35.57% |
2017 | 32.61 Million SEK | -19.43% |
2016 | 40.47 Million SEK | -7.04% |
2015 | 43.54 Million SEK | 105.91% |
2014 | 21.14 Million SEK | 45.0% |
2013 | 14.58 Million SEK | -30.03% |
2012 | 20.84 Million SEK | -3.17% |
2011 | 21.52 Million SEK | 53.46% |
2010 | 14.02 Million SEK | 6.46% |
2009 | 13.17 Million SEK | -31.26% |
2008 | 19.16 Million SEK | 91.13% |
2007 | 10.02 Million SEK | 75.39% |
2006 | 5.71 Million SEK | -10.68% |
2005 | 6.4 Million SEK | 41.86% |
2004 | 4.51 Million SEK | 25.78% |
2003 | 3.58 Million SEK | 214.74% |
2002 | 1.14 Million SEK | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q3 | - SEK | 0.0% |
2024 Q1 | - SEK | -100.0% |
2024 Q2 | - SEK | 0.0% |
2023 FY | 181.2 Million SEK | 26.86% |
2023 Q4 | 181.2 Million SEK | 0.0% |
2023 Q1 | - SEK | -100.0% |
2023 Q3 | - SEK | 0.0% |
2023 Q2 | - SEK | 0.0% |
2022 Q3 | - SEK | 0.0% |
2022 Q4 | 142.83 Million SEK | 0.0% |
2022 FY | 142.83 Million SEK | 39.03% |
2022 Q1 | - SEK | -100.0% |
2022 Q2 | - SEK | 0.0% |
2021 Q1 | - SEK | -100.0% |
2021 FY | 102.73 Million SEK | 42.14% |
2021 Q2 | - SEK | 0.0% |
2021 Q4 | 102.73 Million SEK | 0.0% |
2021 Q3 | - SEK | 0.0% |
2020 Q3 | - SEK | 0.0% |
2020 Q2 | - SEK | 0.0% |
2020 Q4 | 72.27 Million SEK | 0.0% |
2020 Q1 | - SEK | -100.0% |
2020 FY | 72.27 Million SEK | 5.6% |
2019 Q1 | - SEK | -100.0% |
2019 FY | 68.44 Million SEK | 54.81% |
2019 Q4 | 68.44 Million SEK | 0.0% |
2019 Q3 | - SEK | 0.0% |
2019 Q2 | - SEK | 0.0% |
2018 Q4 | 44.21 Million SEK | 0.0% |
2018 Q1 | - SEK | -100.0% |
2018 Q2 | - SEK | 0.0% |
2018 Q3 | - SEK | 0.0% |
2018 FY | 44.21 Million SEK | 35.57% |
2017 Q2 | - SEK | 0.0% |
2017 FY | 32.61 Million SEK | -19.43% |
2017 Q4 | 32.61 Million SEK | 0.0% |
2017 Q3 | - SEK | 0.0% |
2017 Q1 | - SEK | -100.0% |
2016 Q4 | 40.47 Million SEK | 0.0% |
2016 FY | 40.47 Million SEK | -7.04% |
2016 Q3 | - SEK | 0.0% |
2016 Q2 | - SEK | 0.0% |
2016 Q1 | - SEK | -100.0% |
2015 Q4 | 43.54 Million SEK | 0.0% |
2015 Q2 | - SEK | 0.0% |
2015 Q3 | - SEK | 0.0% |
2015 FY | 43.54 Million SEK | 105.91% |
2015 Q1 | - SEK | -100.0% |
2014 FY | 21.14 Million SEK | 45.0% |
2014 Q2 | - SEK | 0.0% |
2014 Q3 | - SEK | 0.0% |
2014 Q4 | 21.14 Million SEK | 0.0% |
2014 Q1 | - SEK | -100.0% |
2013 FY | 14.58 Million SEK | -30.03% |
2013 Q1 | - SEK | -100.0% |
2013 Q4 | 14.58 Million SEK | 0.0% |
2013 Q3 | - SEK | 0.0% |
2013 Q2 | - SEK | 0.0% |
2012 Q1 | - SEK | -100.0% |
2012 Q2 | - SEK | 0.0% |
2012 Q4 | 20.84 Million SEK | 0.0% |
2012 Q3 | - SEK | 0.0% |
2012 FY | 20.84 Million SEK | -3.17% |
2011 FY | 21.52 Million SEK | 53.46% |
2011 Q2 | - SEK | 0.0% |
2011 Q1 | - SEK | -100.0% |
2011 Q4 | 21.52 Million SEK | 0.0% |
2011 Q3 | - SEK | 0.0% |
2010 Q2 | - SEK | 0.0% |
2010 Q3 | - SEK | 0.0% |
2010 FY | 14.02 Million SEK | 6.46% |
2010 Q4 | 14.02 Million SEK | 0.0% |
2010 Q1 | - SEK | -100.0% |
2009 FY | 13.17 Million SEK | -31.26% |
2009 Q4 | 13.17 Million SEK | 0.0% |
2009 Q2 | - SEK | 0.0% |
2008 FY | 19.16 Million SEK | 91.13% |
2007 FY | 10.02 Million SEK | 75.39% |
2006 FY | 5.71 Million SEK | -10.68% |
2005 FY | 6.4 Million SEK | 41.86% |
2004 FY | 4.51 Million SEK | 25.78% |
2003 FY | 3.58 Million SEK | 214.74% |
2002 FY | 1.14 Million SEK | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
AcuCort AB | -1.09 Million SEK | 16588.08% |
AlzeCure Pharma AB (publ) | -2508.00 SEK | 7225139.872% |
Enzymatica AB (publ) | 11.49 Million SEK | -1475.824% |
Enorama Pharma AB (publ) | 4.29 Million SEK | -4121.901% |
Gabather AB (publ) | -1772.00 SEK | 10226059.368% |
Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
Moberg Pharma AB (publ) | 7.11 Million SEK | -2446.788% |
Nanexa AB (publ) | 1.91 Million SEK | -9382.156% |
Newbury Pharmaceuticals AB (publ) | 4.99 Million SEK | -3527.708% |
ODI Pharma AB | - SEK | -Infinity% |
Orexo AB (publ) | 42.4 Million SEK | -327.368% |
Probi AB (publ) | 116.7 Million SEK | -55.267% |
Swedencare AB (publ) | 398.1 Million SEK | 54.483% |
Swedish Orphan Biovitrum AB (publ) | 3.87 Billion SEK | 95.323% |
Toleranzia AB | -1.34 Million SEK | 13622.687% |
Vivesto AB | - SEK | -Infinity% |